Abstract
This follow-up study was carried out to validate the effectiveness of cross-gender hormone therapy embedded in a multistep treatment concept for transsexual patients. This therapy described in detail by the authors elsewhere and presented briefly below provides cross-gender hormone substitution to obtain an assimilation of secondary sex characteristics to the desired sex as quickly as possible. Personal and social background data of 46 male-to-female (M-to-F) and 42 female-to-male (F-to-M) patients passing through different stages of the treatment concept were included. In the Endocrinological Outpatient Clinic of the Max-Planck-Institute/Munich the effectiveness of cross-gender hormone replacement therapy as well as frequency and distribution of side effects were examined by follow-up examination of endocrinological parameters. Cross-gender hormones were administered either parenterally or orally. Blood samples were collected routinely after 2 to 6 months depending on the duration of hormone substitution and complication rate. The incidence of hyperprolactinemia in estrogen-treated M-to-F transsexuals lies in the range of studies published before, whereas the number of patients developing galactorrhea is significantly lower in our patients. The incidence of thromboembolic events during the time of cross-gender hormone treatment in our patients is negligible. Changes in hematological parameters are observed under cross-gender hormone therapy. With the cross-gender hormone regimen performed by us it is possible to generate less side effects in the treatment of transsexual patients than described before.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Alexanian, R. (1969). Erythropoietin and erythropoiesis in anemic man following androgens. Blood 33: 564–572
Asscheman, H., Gooren, L. J. G., Assies, J., Smits, J. P. H., and de Slegte, R. (1988). Prolactin levels and pituitary enlargement in hormone treated male-to-female transsexuals. Clin Endocrinol 28: 583–588.
Asscheman, H., Gooren, L. J. G., and Eklund, P. L. E. (1989). Mortality and morbidity in transsexual patients with cross-gende r hormone treatment. Metabolism 38: 869–873.
Biller, J., and Saver, J. (1995). Ischemic cerebrovascular disease and hormone therapy for infertility and transsexualism. Neurology 45: 1611–1613.
Damewood, M. D., Bellantoni, J. J., Bachorik, P. S., Kinball, A. W. Jr., and Rock, J. A. (1989). Exogenous estrogen effect on lipid/lipoprotein cholesterol in transsexual males. J. Endocrinol Invest. 12: 449–454.
de Gowin, R., Richard, L., Lavender, A. R., Forland, M., and Charleston, D. (1970). Erythropoietin and erythropoiesis in patients with chronic renal failure treated with hemodialysis and testosterone. Ann. Intern. Med. 72: 913–918.
de Marinis, M., and Arnett, E. N. (1978). Cerebrovascular occlusion in a transsexual man taking me stranol. Arch. Intern. Med. 138: 1732–1733.
Dixen, J. M., Maddever, H., van Maasdam, J., and Edwards, P. W. (1984). Psychosocial characteristics of applicants evaluated for surgical cross-gender re assignment. Arch. Sex. Behav. 13: 269–276.
Fleming, M., Cohen, D., Salt, P., Jones, D., and Jenkins, S. (1981). A study of pre-and postsurgical transsexuals: MMPI characteristics. Arch. Sex. Behav. 10: 161–170.
Fortin, C. L., Klein, T., Messmore, H. L., and O'Connell, J. B. (1984). Myocardial infarction and severe thromboembolic complications as seen in an estrogen-dependent transsexual. Arch. Intern. Med. 144: 1082–1083.
Fried, W., Jonasson, O., and Lang, G. (1973). The hematological effect of androgen in uremic patients. Ann. Intern. Med. 79: 823–827.
Futterweit, W. (1980). Endocrine management of the transsexual. N.Y. State J. Med. 80: 1260–1264.
Glashan, R. W., and Robinson, M. R. G. (1981). Cardiovascular complications in the treatment of prostatic carcinoma. Br. J. Urol. 53: 624–627.
Goh, H. H., Loke, D. F. M., and Ratnam, S. S. (1995). The impact of long-term testosterone replaceme nt therapy on lipid and lipoprotein profiles in women. Maturitas 21: 65–70.
Goodwin, W. E., and Cummings, R. H. (1984). Squamous metaplasia of the verumontanum with obstruction due to hypertrophy: long-term effects of estrogen on the prostate in an aging male-to-female transsexual. J. Urol. 131: 553–554.
Gooren, L. (1990). The endocrinology of trans sexualism: Review and commentary. Psychoneuroend ocrinology 15: 3–14.
Gooren, L. J. G., van der Veen, E. A., and van Kessel, H. (1980). Modulation of prolactin secretion by gonadal steroids in men. In: MacLeod, R. M., and Scapagnini, U. (eds.), Central and Peripheral Regulation of Prolactin Function, Raven Press, New York, pp.373–375.
Green, R. (1966). Mythological, historical, and cross-cultural aspects of transsexualism. In Benjamin H. The Transsexual Phenomenon. The Julian Press, New York.
Hannaford, P. C., Croft, P. R., and Kay, C. R. (1994). Oral contraception and stroke. Stroke 25: 935–942.
Hoenig, J., and Kenna, J. (1973). Epidemiological aspects of transsexualism. Psychiat. Clin. 6: 65–80.
Kennedy, B. J., and Gilbertsen, S. (1957). Increased erythropoesis induced by androgenic hormone therapy. New. Engl. J. Med. 256: 719–726.
Kockott, G., and Fahrner, E. M. (1988). Male-to-female and female-to-male transsexuals: A comparison. Arch. Sex. Behav. 17: 539–546.
Kovacs, K., Stefaneanu, L., Ezzat, S., and Smyth, H. S. (1994). Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. Arch. Pathol. Lab. Med. 118: 562–565.
Lehrman, K. L. (1976). Pulmonary embolism in a transsexual man taking diethlstilbestrol. J. Am. Med. Assoc. 235: 532–533.
Meyer, W. J., Webb, A., and Stuart, C. A. (1986). Physical and hormonal evaluation of the transsexual patient. A longitudinal study. Arch. Sex. Behav. 15: 121–138.
Pauly, I. (1965). Male psychosexual inversion: Transsexualism. Arch. Gen. Psychiat. 13: 172–181.
Pauly, I. B. (1968). The current status of the sex change operation. J. Nerv. Ment. Dis. 147: 460–471.
Pauly, I. B. (1974). Female transsexualism I and II. Arch. Sex. Behav. 3: 487–526.
Pritchard, T. J., Pankowsky, D. A., Crowe, J. P., and Abdul-Karim, F. W. (1988). Breast cancer in a male-to-female transsexual. A case report. J. Am. Med. Assoc. 259: 2278–2280.
Schlatterer, K., von Werder, K., and Stalla, G. K. (1996). Multistep treatment concept of transsexual patients. Exp. Clin. Endocrinol. (in press).
Stadel, B. V. (1981). Oral contraceptives and cardiovascular disease. New Engl. J. Med. 305: 612–618, 672–677.
Symmers, W. C. (1968). Carcinoma of the breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br. Med. J. 2: 83–85.
Tsoi, W. F. (1990). Developmental profile of 200 male and 100 female transsexuals in Singapore. Arch. Sex. Behav. 19: 595–605.
Tsoi, W. F. (1992). Male and female transsexuals: A comparison. Singapore Med. J. 33: 182–185.
Rights and permissions
About this article
Cite this article
Schlatterer, K., Yassouridis, A., Werder, K.V. et al. A Follow-Up Study for Estimating the Effectiveness of a Cross-Gender Hormone Substitution Therapy on Transsexual Patients. Arch Sex Behav 27, 475–492 (1998). https://doi.org/10.1023/A:1018704630036
Issue Date:
DOI: https://doi.org/10.1023/A:1018704630036